EU approvals for Spiolto Respimat (tiotropium/olodaterol) for treatment of COPD- Boehringer
Boehringer Ingelheim announced regulatory authority approvals for Spiolto Respimat (tiotropium/olodaterol) in first European countries. Spiolto Respimat is a once-daily maintenance treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). Approvals of the treatment in other European countries are expected to follow in the coming months. Spiolto Respimat provides significant improvements in lung function, breathlessness, quality of life and rescue medication use over Spiriva (tiotropium) right from the initial stages when patients need maintenance therapy. These additional benefits could enable patients to remain active and avoid the downward spiral of COPD for as long as possible.
Spiolto Respimat has now been given approval in nine European countries � UK, Ireland Croatia, Slovakia, Denmark, Norway, Austria, Romania and Spain.
Comment: The FDA approved the combination as Stiolto Respimat for COPD in May 2015.
530 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.